DJIA 17,164.95 -251.90 -1.45%
NASDAQ 4,635.24 -48.17 -1.03%
S&P 500 1,994.99 -26.26 -1.30%
market minute promo

Antares Pharma, Inc. (NASDAQ: ATRS)



company name or ticker

Antares Pharma Awarded Additional U.S. Patent Protection for OTREXUP™

Antares Marketing Agreement With Leo On Otrexup Is A Nice Positive

Antares: Thoughts On The Upcoming Otrexup Launch

Antares Pharma Management Discusses Q3 2013 Results - Earnings Call Transcript

The Next Great Growth Companies On Big Pharma's Radar

Antares Pharma Announces Issuance of Patent for VIBEX Device Platform

This Week in Biotech

Two Food and Drug Administration drug approvals, a cholesterol-lowering drug impresses in a big way, and two biotechs getting slaughtered following a disappointing clinical update are this week's top biotech stories.

Is This New Rheumatoid Arthritis Treatment a Game Changer?

Antares Pharma just patented a self-injectable version of a widely available generic drug. Can this new treatment decrease the company’s dependence on its larger generic customers?

Our Best Small-Cap Biotech Picks For The Rest Of This Year

Will Antares' FDA Decision Mean Good News for Arthritis Patients?

AbbVie probably isn't quaking in its boots with the FDA's decision to approve Antares' Otrexup. However, this could be great news for arthritis and psoriasis patients.
See More Articles...